Virpax Pharmaceuticals, Inc. - VRPX
About Gravity Analytica
Recent News
- 03.07.2025 - Virpax Looking to Use MET to Develop Intranasal COVID Vaccine
- 03.05.2025 - Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS
- 02.27.2025 - Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology
- 02.13.2025 - Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study
- 01.31.2025 - Virpax’s Matthew Barnes to Present at Outsourcing in Clinical Trials Conference
- 01.30.2025 - Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants
- 01.30.2025 - Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants
- 01.28.2025 - Virpax Pharmaceuticals, Inc. Announces Pricing of $6 Million Public Offering of Common Stock and Pre-Funded Warrants
- 01.28.2025 - Virpax Pharmaceuticals, Inc. Announces Pricing of $6 Million Public Offering of Common Stock and Pre-Funded Warrants
- 01.28.2025 - Virpax Pharmaceuticals, Inc. Announces Pricing of $6 Million Public Offering of Common Stock and Pre-Funded Warrants
Recent Filings
- 03.03.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
- 02.06.2025 - 8-K Current report
- 02.04.2025 - 8-K Current report
- 01.30.2025 - EX-99.1 EX-99.1
- 01.30.2025 - 8-K Current report
- 01.28.2025 - 424B4 Prospectus [Rule 424(b)(4)]
- 01.27.2025 - EFFECT Notice of Effectiveness
- 01.22.2025 - CORRESP Correspondence
- 01.22.2025 - CORRESP Correspondence
- 01.17.2025 - S-1/A General form for registration of securities under the Securities Act of 1933